🇺🇸 FDA
Pipeline program

KIO-101

KIO-101-2201

Phase 2 small_molecule terminated

Quick answer

KIO-101 for Dry Eye Disease is a Phase 2 program (small_molecule) at KIORA PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
KIORA PHARMACEUTICALS INC
Indication
Dry Eye Disease
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials